1. Home
  2. WLKP vs CAPR Comparison

WLKP vs CAPR Comparison

Compare WLKP & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Westlake Chemical Partners LP

WLKP

Westlake Chemical Partners LP

HOLD

Current Price

$19.83

Market Cap

652.0M

Sector

Industrials

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$26.07

Market Cap

324.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WLKP
CAPR
Founded
2014
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
652.0M
324.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
WLKP
CAPR
Price
$19.83
$26.07
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$37.75
AVG Volume (30 Days)
64.9K
5.8M
Earning Date
10-30-2025
11-10-2025
Dividend Yield
9.54%
N/A
EPS Growth
N/A
N/A
EPS
1.39
N/A
Revenue
$1,133,706,000.00
$11,130,509.00
Revenue This Year
$3.88
N/A
Revenue Next Year
$12.71
$7,736.03
P/E Ratio
$14.17
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.75
$4.30
52 Week High
$25.04
$40.37

Technical Indicators

Market Signals
Indicator
WLKP
CAPR
Relative Strength Index (RSI) 63.97 71.27
Support Level $18.88 $4.30
Resistance Level $19.19 $29.23
Average True Range (ATR) 0.38 3.27
MACD 0.17 1.66
Stochastic Oscillator 86.29 60.24

Price Performance

Historical Comparison
WLKP
CAPR

About WLKP Westlake Chemical Partners LP

Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develops ethylene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: